drugset / Trial / NCT07333352
PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
RandomizedParallel-groupTriple-blindPrevention
Summary
The Phase II clinical trial of the 24-valent pneumococcal polysaccharide conjugate vaccine (RZ700) will be carried out in infants and young children aged 2 months (minimum 6 weeks) to 71 months. The purpose of this study is to evaluate the immunogenicity and safety of the 24-valent pneumococcal polysaccharide conjugate vaccine.
Timeline
- Start
- 2025-09-11
- Primary completion
- 2027-07
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |
| Subject | RZ700 | Vaccine | 0.5 ml | Intramuscular |